TMCnet News
China In-Vitro Diagnostics Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021 - Research and MarketsResearch and Markets has announced the addition of the "China In Vitro Diagnostics(IVD) - Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021" report to their offering. The in-vitro diagnostics(IVD) market in China has been growing rapidly in the past few years and is expected to grow steadily in the next few years, with major growth potential in segments such as infectious disease testing, chronic disease testing and diagnosis in early stages of disease. Some of the major factors driving the growth of this market are the rising incidences of chronic lifestyle diseases, public health awareness, growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high-end products and an increase in the number of private hospitals and independent testing laboratories. However, low reimbursement rate, absence of quality products by the local companies, population factors and foreign companies faces difficulty to enter the low end IVD products market are restraining the growth of this market. Other segments such as Clinical Chemistry, Molecular testing and POCT are poised to be remarkable expansion in the near futue. Growing demand for infectious disease testing, chronic disease testing and diagnosis in early stages of disease will usher the China IVD market. Sysmex Corporation and Abbott Laboratories are the other top two players in the China IVD market. Mindray and Shanghai Kehua Bioengineering(KHB) are another major participant in this market with a good hold in clinical chemistry, immunoassay and molecular testing segments providing varieties of reagents nationwide and semi-auto and automatic biochemistry analyzers to low and mid-end market users. The following segments of the China In Vitro Diagnostics market are detailed with size and six year forecast: - Clinical Chemistry - Immunoassay - Molecular Testing - Self-Monitoring of Blood Glucose (SMBG) - Point of Care Testing (POCT) - Hematology - Coagulation - Microbiology The following companies of the China In Vitro Diagnostics market are detailed with size and six year forecast: - Roche Diagnostics - Abbott Laboratories - Mindray Medical International Limited - Sysmex Corporation - Shanghai Kehua Bio-Engineering Co. Ltd. - Other Companies The following Chinese companies of the China In Vitro Diagnostics market are detailed with company overview and its product portfolio: - Mindray Medical International Limited - Shanghai Fosun Pharmaceutical Group - Mingyuan Medicare - Da An Gene Co. Ltd. - Shanghai Kehua Bio-Engineering Co. Ltd. - Zhejiang D.a. Diagnostics Technology Co., Ltd - ADICON Clinical Laboratories - Guangzhou Kingmed Diagnostics Center Co. Ltd. - Kindstar Global - BGI - Shenzhen - OriGene Technologies For more information about this report visit http://www.researchandmarkets.com/research/rqrqtl/china_in_vitro Related Topics: In Vitro Diagnostics
View source version on businesswire.com: http://www.businesswire.com/news/home/20160823005965/en/ |
